Serum fetuin-A levels are associated with serum triglycerides before and 6 months after bariatric surgery

Verras, Christos; Christou, Georgios A; Simos, Yannis V.; Ayiomamitis, Georgios D.; Μelidonis, Αndreas; Kiortsis, Dimitrios N.

doi:10.14310/horm.2002.1739

Cited by 7 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides the described imaging techniques, liver biomarkers are in discussion to be helpful in the diagnosis and monitoring of fatty liver diseases. In this trial, Fetuin A concentrations did not change 6 months postsurgery, which is in line with other previous trials studying short-term effects of bariatric surgery on Fetuin A [33]. In contrast, in the long-term (> 12 months), Fetuin A seems to decrease as shown by other groups [34, 35].…”

Section: Resultssupporting

confidence: 91%

Quantification of Liver, Subcutaneous, and Visceral Adipose Tissues by MRI Before and After Bariatric Surgery

et al. 2019

View full text Add to dashboard Cite

Background Morbid obesity is a worldwide epidemic and is increasingly treated by bariatric surgery. Fatty liver is a common finding; almost half of all patients with non-alcoholic steatohepatitis develop steatohepatitis. Bariatric surgery improves steatohepatitis documented by liver biopsy and single voxel magnetic resonance imaging (MRI) techniques. Objective To investigate changes before and after bariatric surgery using whole organ MRI quantification of liver, visceral, and subcutaneous fat. Setting University of Basel Hospital and St. Clara Research Ltd, Basel, Switzerland. Methods Sixteen morbidly obese patients were evaluated by abdominal MRI-scanning before and 3, 6, 12, and 24 months after bariatric surgery to measure percentage liver fat (%-LF), total liver volume (TLV) and visceral and subcutaneous adipose tissues (VAT and SAT). Fasting plasma samples were taken for measurement of glucose, insulin, blood lipids, and liver biomarkers. In a control group of 12 healthy lean volunteers, the liver biomarker was also measured. Results The reproducibility of fat quantification by use of MRI was excellent. LF decreased significantly faster than VAT and SAT (%-LF vs. VAT p < 0.001 and %-LF vs. SAT p < 0.001). At certain time points, %-LF, VAT, and SAT were associated with changes in blood lipids and insulin. Conclusions MRI quantification offers excellently reproducible results in measurement of liver fat and visceral and subcutaneous adipose tissues. Liver fat decreased significantly faster than visceral or subcutaneous adipose tissue. Decrease in %-LF and VAT is associated with decrease in total cholesterol, LDL, and plasma insulin. Electronic supplementary material The online version of this article (10.1007/s11695-019-03897-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultssupporting

confidence: 91%

Quantification of Liver, Subcutaneous, and Visceral Adipose Tissues by MRI Before and After Bariatric Surgery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In the obese, the concentration of fetuin-A has been shown to increase at four months ( Kahraman et al, 2013 ), remain unchanged at six months ( Kahraman et al, 2013 ), decrease at 12 months ( Yang et al, 2015 ), or decrease at 16 months ( Brix et al, 2010 ) in the morbidly obese after GB ( Table 5 ). On the other hand, fetuin-A has also been showed to be either unchanged at 6 months ( Verras et al, 2017 ) or decreased at 12 months ( Yang et al, 2015 ) in the morbidly obese after SG. These results regarding fetuin-A levels after either GB or SG are very inconsistent.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, fetuin-A levels are correlated with IR, obese T2D, and metabolic liver disease. After bariatric surgery, the changes in fetuin-A levels are not consistent and can either decrease ( Brix et al, 2010 ; Jüllig et al, 2014 ; Yang et al, 2015 ) or remain unaffected ( Kahraman et al, 2013 ; Verras et al, 2017 ). These discordant observations need further investigation.…”

Section: Introductionmentioning

confidence: 99%

Does bariatric surgery influence plasma levels of fetuin-A and leukocyte cell-derived chemotaxin-2 in patients with type 2 diabetes mellitus?

Huang

Yeh

Chen

et al. 2018

PeerJ

View full text Add to dashboard Cite

BackgroundFetuin-A and leukocyte cell-derived chemotaxin-2 (LECT-2) are liver-derived proteins. Fetuin-A is an independent risk factor for type 2 diabetes (T2D) and obese patients with T2D have higher plasma fetuin-A levels than those without T2D. LECT-2 has positive correlation with the severity of both obesity and insulin resistance. The changes in plasma fetuin-A are not consistent after bariatric surgery and no studies have investigated the changes in LECT-2 on the obese patients with T2D after bariatric surgery.MethodsOverall, 18 patients undergoing gastric bypass (GB) and 16 patients undergoing sleeve gastrectomy (SG) were enrolled. The fasting plasma fetuin-A and LECT-2 levels were measured at baseline, one week, three months, and one year after surgery.ResultsBoth the GB and SG groups significantly decreased the body mass index (BMI), waist-to-hip ratio, a body shape index; the triglyceride, fasting blood sugar (FBS), hemoglobin A1c, C-peptide levels; and homeostatic model assessment (HOMA-IR) one year after surgery. The SG group showed a decreasing trend in plasma fetuin-A levels one year after SG surgery. There are no significant changes in LECT-2 one year after either GB or SG. Fetuin-A had a near significant negative relationship with insulin (P = 0.056) and HOMA-IR (P = 0.050) in the SG group. Changes in fetuin-A had a significant positive relationship with changes in BMI (P = 0.031) and waist-to-hip ratio (P = 0.031) in the GB group and had a near significant positive correlation with FBS (P = 0.051) in the SG group.DiscussionNeither GB nor SG modifies plasma levels of plasma fetuin-A or LECT-2 in T2D patients after surgery. The changes in plasma fetuin-A have a positive correlation with those of the BMI and waist-to-hip ratio 12 months after GB.

show abstract

“…Активно обсуждается роль гепатокинов в патогенетическом каскаде формирования прогноза как самой НАЖБП, так и связанных с ней коморбидных состояний [56]. Эпидемиологические исследования показали, что фетуин-A и фетуин-B играют важную роль в развитии ожирения, гипергликемии и гипертриглицеридемии, способствуют формированияю МС, сахарного диабета 2 типа и сердечно-сосудистых заболеваний (ССЗ) [57][58][59][60], являясь комплексными реагентами метаболической фазы развития и прогрессирования как самой НАЖБП, так и коморбидных патологий. Существует предположение, что фетуин-A является связующим звеном между ожирением, инсулинорезистентностью и НАЖБП.…”

unclassified

NAFLD Associated Comorbidity

Лазебник

Туркина

2021

jour

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is considered not only as a disease with poor hepatic prognosis. The problem has acquired a multidisciplinary problem. The variety of concomitant diseases and pathological conditions are united by common pathophysiological mechanisms.This review summarizes and presents the data available in the modern literature on the association of NAFLD with cardiovascular diseases, type 2 diabetes mellitus, polycystic ovary syndrome, chronic kidney disease, etc. The role of the liver in the homeostasis of the organism and the pathogenetic mechanisms of the formation of NAFLD-associated comorbidity are discussed.

show abstract

Serum fetuin-A levels are associated with serum triglycerides before and 6 months after bariatric surgery

Cited by 7 publications

References 36 publications

Quantification of Liver, Subcutaneous, and Visceral Adipose Tissues by MRI Before and After Bariatric Surgery

Quantification of Liver, Subcutaneous, and Visceral Adipose Tissues by MRI Before and After Bariatric Surgery

Does bariatric surgery influence plasma levels of fetuin-A and leukocyte cell-derived chemotaxin-2 in patients with type 2 diabetes mellitus?

NAFLD Associated Comorbidity

Contact Info

Product

Resources

About